JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Allist Pharmaceuticals, Inc.
Study ID
NCT04720976
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JAB-3312 — DRUG
    JAB-3312 will be administered orally, variable dose.
  • Binimetinib — DRUG
    Binimetinib will be administered orally.
  • Pembrolizumab — DRUG
    Pembrolizumab will be administered as an intravenous infusion.
  • Sotorasib — DRUG
    Sotorasib will be administered orally.
  • Osimertinib — DRUG
    Osimertinib will be administered orally.

Study Details

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

Key Dates

Start date
Mar 23, 2021
Status verified
Mar 2025
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023

Study Design

Enrollment
58 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: JAB-3312+Pembrolizumab dose escalation
    Dose escalation
  • Experimental: JAB-3312+ Binimetinib dose escalation
    Dose escalation
  • Experimental: JAB-3312+Pembrolizumab dose expansion
    Dose expansion
  • Experimental: JAB-3312+Binimetinib dose expansion
    Dose expansion
  • Experimental: JAB-3312+Sotorasib dose escalation
    Dose escalation
  • Experimental: JAB-3312+ Osimertinib dose escalation
    Dose escalation
  • Experimental: JAB-3312+ Sotorasib dose expansion
    Dose expansion
  • Experimental: JAB-3312+ Osimertinib dose expansion
    Dose expansion

Primary Outcome Measure

Number of participants with dose limiting toxicities [ Time Frame: 24 months ]

Locations (15)

FacilityCityStateZIPSite coordinators
Research SitePhoenixArizona85054-
Research SiteScottsdaleArizona85259-
Research SiteLos AngelesCalifornia90033-
Research SiteNew HavenConnecticut06510-
Research SiteJacksonvilleFlorida32224-
Research SiteOrange CityFlorida32763-
Research SiteChicagoIllinois60637-
Research SiteIndianapolisIndiana46202-
Research SiteDetroitMichigan48202-
Research SiteRochesterMinnesota55902-
Research SiteSt LouisMissouri63130-
Research SiteNew YorkNew York10016-
Research SiteOklahoma CityOklahoma73104-
Research SiteHoustonTexas77030-
Research SiteSalt Lake CityUtah84112-

Find similar trials in Phoenix, AZ

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Research Site· Phoenix, AZResearch Site· Scottsdale, AZResearch Site· Los Angeles, CAResearch Site· New Haven, CTResearch Site· Jacksonville, FLResearch Site· Orange City, FL

Related Studies